University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 9L-16-3


A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Other
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Casey O'Connell, M.D.
Other Trial Staff:  John Lee, D.M., Ashot Minasyan, D.M., Christine Duran, D.M., Donna Fernando, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.